티디에스팜

464280KOSDAQ

58.5 / 100

Reference Date: 2026-10-23

Financial Score30.0 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue metrics are weak. Declined 6.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

TDS Pharm specializes in the development and manufacturing of transdermal drug delivery systems (TDDS), holding a leading position in the Korean market with key products like Cataplasma and Plaster. The company aims to grow into a global pharmaceutical firm by expanding its portfolio to include patches targeting dementia, asthma, nicotine addiction, and other therapeutic areas.

Number of Employees

111people

Average Salary

32.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

6.71Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

0.67Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

10.52Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

0.38Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~20254.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.4% (1-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.9% (1-year basis)

ROE Trend

2.5 / 4

Avg ROE 11.3% (declining, 2yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 5,190Won52-week high 10,50052-week low 4,525

1-month return2.0Point

1m -6.49% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral주주명부폐쇄기간또는기준일설정2026-09-30